Anuh Pharma Limited has informed the Exchange regarding 'Financial Results'.
ANUHPHR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Anuh Pharma reported annual revenue of Rs 77,166 Lakhs for FY26, up 16.6% from Rs 66,151 Lakhs in FY25. However, profit after tax declined 13.3% to Rs 4,105 Lakhs from Rs 4,735 Lakhs due to higher input costs and raw material expenses. EBITDA margin compressed to 8.56% from 10.64% in the prior year. The company completed a 1:1 bonus share issuance in July 2025, doubling share capital to Rs 5,011 Lakhs. The board recommended a dividend of Rs 1.50 per share. Inventories nearly doubled to Rs 14,776 Lakhs while operating cash flow turned negative at Rs -301 Lakhs due to working capital buildup. Auditors issued an unqualified (clean) opinion.
While revenue growth demonstrates business expansion, the decline in profitability and margin compression signal cost pressures that concern investors. The sharp rise in inventory and negative operating cash flow may require monitoring. The clean audit opinion provides assurance on financial reporting quality.